ALNYLAM PHARMACEUTICALS INC

Alnylam’s RNA‑i tech shows promise in cardiology, yet mixed trial data and stiff PCSK9 competition keep investors on watch‑for‑Phase‑3 approvals.

Alnylam gains Outperform ratings as BMO & Benzinga boost its RNAi‑powered ATTR pipeline, positioning the biotech stock for strong growth.

Alnylam’s RNA‑i promise vs. reality: explore why the biotech’s lofty P/E and hype miss the mark on commercial breakthroughs and competitive pressure.

Alnylam’s new partnership with Tenaya Therapeutics extends funding into 2027, opening doors for future milestone and reimbursement deals while advancing gene‑therapy research.

Alnylam’s vutrisiran shows promising results for ATTR‑CM, boosting RNAi therapy prospects while a key leadership shift raises questions about its future pipeline strategy.

Alnylam partners with Viz.ai and the AHA to launch AI‑driven tools for early ATTR‑CM detection, boosting diagnosis, treatment timing and clinical outcomes.

Alnylam Pharmaceuticals sees rising short‑interest and insider sales while its amyloidosis drug and 2026 outlook spark cautious investor curiosity.

Alnylam Pharmaceuticals joins the Nasdaq 100, boosting liquidity, index‑fund exposure, and analyst confidence, while its RNA‑i pipeline and strategic buybacks signal growth in a $73B non‑opioid therapeutics market.

Alnylam’s Q3 earnings jump 149% with Amvuttra sales, up‑raised 2025 revenue guidance, and a strong 52‑week high – a biotech surge worth watching.

Alnylam Pharmaceuticals Inc. is revolutionizing the treatment of cardiovascular diseases with its innovative drugs Zilebesiran and AMVUTTRA, which are showing promising results in clinical trials and poised to transform the management of hypertensio…